View : 88 Download: 0
The novel NMDA receptor antagonist, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4- trifluoromethyl-benzylamino)-benzoic acid, is a gating modifier in cultured mouse cortical neurons
- The novel NMDA receptor antagonist, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4- trifluoromethyl-benzylamino)-benzoic acid, is a gating modifier in cultured mouse cortical neurons
- Noh J.; Lee E.-S.; Chung J.-M.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- Journal of Neurochemistry
- vol. 109, no. 5, pp. 1261 - 1271
- SCI; SCIE; SCOPUS
- Neu2000 [NEU, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl- benzylamino)-benzoic acid], a derivative of sulfasalazine, attenuates NMDA-induced neuronal toxicity. Here we investigated the effects of NEU on the NMDA receptor (NMDAR) using whole-cell patch clamp technique to determine the molecular mechanisms underlying its neuroprotective role. NEU reversibly suppressed NMDA responses in an uncompetitive manner with fast binding kinetics. Its inhibition of NMDAR activity depended on both the concentration and the use of agonist but not on the membrane potential. NEU accelerated NMDA desensitization without affecting the binding affinity of NMDAR for its agonists and stabilized the closed state of NMDAR. Therefore, NEU should effectively alleviate disorders that are a result of glutamate excitoxicity with fewer side effects because it is a low-affinity gating modifier that antagonizes NMDAR in an uncompetitive manner. Moreover, in the presence of ifenprodil (an NR2B antagonist) but not NVP-AAM077 [(R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3- dioxo-1,2,3,4-tetrahydro-quinoxalin-5-yl)-methyl]-phosphonic acid, an NR2A antagonist], the extent of NEU block was decreased, suggesting that NEU is an NR2B-specific antagonist. © 2009 International Society for Neurochemistry.
- Appears in Collections:
- 자연과학대학 > 생명과학전공 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.